Company intelligence / Profile preview
MalarVx
Seattle, Washington, United Statesmalarvx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical studies in mouse models show that the prime-and-trap vaccine approach—using repRNA/LION nanocarrier and radiation-attenuated sporozoites—induces robust, durable immune responses and >80% sterile protection in accelerated dosing regimens. Mice challenged after same-day immunization showed 90% sterile protection at three weeks and 70% at two months. MalarVx is entering late-stage preclinical and clinical development.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Self-amplifying replicon RNA (repRNA)VaccineLipid nanoparticle (LION™)Radiation-attenuated whole organism parasite (Radiation Attenuated Sporozoite)Genetically attenuated parasite
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
HDT Bio (for LION™ platform and repRNA technology)
Beyond the preview
Go deeper on MalarVx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MalarVx.